A2A Pharmaceuticals

New York, United States Founded: 2016 • Age: 10 yrs
proprietary fragment based computational drug discovery platform for antibiotic resistance

About A2A Pharmaceuticals

A2A Pharmaceuticals is a company based in New York (United States) founded in 2016 by Matthew Welsch and Edward Painter.. A2A Pharmaceuticals has raised $250 thousand across 1 funding round from investors including IndieBio. The company has 5 employees as of December 31, 2024. A2A Pharmaceuticals offers products and services including AI Computational System, MLL-Menin Program, and COVID-19 Inhibitors. A2A Pharmaceuticals operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Paratek Pharma and Antheia, among others.

  • Headquarter New York, United States
  • Employees 5 as on 31 Dec, 2024
  • Founders Matthew Welsch, Edward Painter
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name A2a Pharmaceuticals Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $250 K (USD)

    in 1 rounds

  • Latest Funding Round
    $250 K (USD), Seed

    Oct 07, 2016

  • Investors
  • Employee Count
    5

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of A2A Pharmaceuticals

A2A Pharmaceuticals offers a comprehensive portfolio of products and services, including AI Computational System, MLL-Menin Program, and COVID-19 Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for accelerating novel drug discovery using AI

AI-based initiative for cancer drug alternatives

Development of Mpro inhibitors for infectious diseases

People of A2A Pharmaceuticals
Headcount 1-10
Employee Profiles 4
Employee Profiles
People
Emmanuel Cruz
Head of Technology Innovation
People
Robbin Frnka
Vice President Of Clinical Operations
People
Sridhar Vempati
Co-founder
People
Sotirios Stergiopoulos
Founder, President & CEO

Unlock access to complete

Funding Insights of A2A Pharmaceuticals

A2A Pharmaceuticals has successfully raised a total of $250K through 1 strategic funding round. The most recent funding activity was a Seed round of $250 thousand completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $249,997
  • First Round

    (07 Oct 2016)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2016 Amount Seed - A2A Pharmaceuticals Valuation IndieBio
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in A2A Pharmaceuticals

A2A Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include IndieBio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Biotech startups are accelerated through IndieBio's focused programs.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by A2A Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - A2A Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

A2a Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of A2A Pharmaceuticals

A2A Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Paratek Pharma and Antheia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Therapeutics for antimicrobial resistant infections are developed.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about A2A Pharmaceuticals

When was A2A Pharmaceuticals founded?

A2A Pharmaceuticals was founded in 2016.

Where is A2A Pharmaceuticals located?

A2A Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.

Is A2A Pharmaceuticals a funded company?

A2A Pharmaceuticals is a funded company, having raised a total of $250K across 1 funding round to date. The company's 1st funding round was a Seed of $250K, raised on Oct 07, 2016.

How many employees does A2A Pharmaceuticals have?

As of Dec 31, 2024, the latest employee count at A2A Pharmaceuticals is 5.

What does A2A Pharmaceuticals do?

A2A Pharmaceuticals was founded in 2016 in New York, United States, within the biopharma sector. Novel drugs are developed to address antibiotic-resistant infections, tuberculosis, and cancer needs. A proprietary SCULPT platform integrates target data to construct and evaluate small molecule libraries iteratively. The preclinical pipeline encompasses oncology candidates AO-001 and AO-102, alongside antibiotic programs targeting LpxC and AroK in gram-negative bacteria.

Who are the top competitors of A2A Pharmaceuticals?

A2A Pharmaceuticals's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

What products or services does A2A Pharmaceuticals offer?

A2A Pharmaceuticals offers AI Computational System, MLL-Menin Program, and COVID-19 Inhibitors.

Who are A2A Pharmaceuticals's investors?

A2A Pharmaceuticals has 1 investor. Key investors include IndieBio.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available